The pooled analysis of data from two clinical studies has once again proven the effectiveness of an innovative antiviral nasal spray used to treat the common cold. Both the duration of cold infections and the number of patients with symptoms were clearly reduced by the use of the nasal spray developed by the Viennese biotech company Marinomed.
The effectiveness of the safe and well-tolerated nasal spray was shown to be comparable in adults and children. The results provide an impressive validation of the potential of the MAVIREX® technology platform, on which the spray is based. The comprehensive data analysis is being presented today at the renowned Macrae Foundation’s XV International Symposium on Respiratory Viral Infections in Rotterdam.
Viennese biotech company Marinomed Biotechnologie GmbH will present the results of a pooled analysis of data from two clinical studies on its antiviral nasal spray for the first time today. The two studies included both adults and children aged between one and 18 years. The studies were carried out at the Department of Otolaryngology at the Medical University of Vienna (adults) and St. Anna’s Children’s Hospital, Vienna (children). A total of 415 patients suffering from the early stages of a cold were treated in two randomised, double-blind, and placebo-controlled studies. The pooled analysis is based on the data for the 254 patients from the intention-to-treat (ITT) population suffering from a viral infection.
This latest data analysis once again demonstrates the impressive effect of the nasal spray, which is based on Carragelose®, a natural substance derived from red algae. The duration of colds in patients treated with the antiviral nasal spray was approximately two days shorter than in those treated with placebo. Even more impressive is the comparison of the data recorded on day 21 after the onset of the cold: While one sixth of patients given the placebo were still ill, only one twentieth – and thereby significantly fewer – of the patients treated with Carragelose® remained so.
Commenting on the new results, the CEO of Marinomed, Dr. Andreas Grassauer, says: “These new data confirm the previous findings and provide additional proof of the broad antiviral effect of the nasal spray. Specific data analyses of patients suffering from rhinovirus, coronavirus and influenza virus infections show that the product is effective irrespective of the virus type.” In this way, it was possible to demonstrate the reduction in the duration of the illness in all three patient groups thanks to the use of the Carragelose® nasal spray.”
These new data on the effectiveness of the antiviral nasal spray are being presented to experts at the renowned Macrae Foundation’s XV International Symposium on Respiratory Viral Infections in Rotterdam today. Based on the analyses previously carried out on the two individual studies, Marinomed has already been able to present convincing data on the effectiveness and safety of the product to numerous drug-approving authorities and the nasal spray has already been approved for over-the-counter sale in 39 countries. Regarding the commercial success of the product, Dr. Grassauer comments: “The MAVIREX® technology platform has proven its potential. Our future developments will now include products for the treatment of influenza and combination products for allergic patients.”